Paul J. Brockelmann

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications

BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

Journal: British journal of haematology
Published: June 23, 2026

Correction: Innovative Exercise in Routine Cancer Care: Insights from Eight Years of Integrated Oncological Exercise Therapy (OTT).

Correction: Innovative Exercise in Routine Cancer Care: Insights from Eight Years of Integrated Oncological Exercise Therapy (OTT).

Journal: Sports medicine - open
Published: June 15, 2026

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

Journal: Cancer
Published: March 21, 2026

Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.

Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.

Journal: Blood advances
Published: February 18, 2026

Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.

Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.

Journal: Blood advances
Published: February 18, 2026

Comparison and combination of prognostic scores for nodular lymphocytepredominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Comparison and combination of prognostic scores for nodular lymphocytepredominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Journal: Haematologica
Published: January 29, 2026

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review.

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review.

Journal: Journal of patient-reported outcomes
Published: November 01, 2025

Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Journal: Blood advances
Published: October 10, 2025

Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Journal: Blood advances
Published: October 10, 2025

Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.

Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.

Journal: Blood
Published: September 25, 2025

Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial.

Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial.

Journal: Blood
Published: September 25, 2025

Four Months of Exercise Intervention Improved Visuomotor, Functional and Cardiorespiratory Capacity in a Patient with Metastatic Uveal Melanoma.

Four Months of Exercise Intervention Improved Visuomotor, Functional and Cardiorespiratory Capacity in a Patient with Metastatic Uveal Melanoma.

Journal: Reports (MDPI)
Published: September 15, 2025
Showing 1-12 of 115

Last Updated: 09/26/2026